Candida infective endocarditis

NIH Public Access Author Manuscript Eur J Clin Microbiol Infect Dis. Author manuscript; available in PMC 2009 October 6.

NIH-PA Author Manuscript

Published in final edited form as: Eur J Clin Microbiol Infect Dis. 2008 July ; 27(7): 519–529. doi:10.1007/s10096-008-0466-x.

Candida Infective Endocarditis John W. Baddley, MD1,2, Daniel K. Benjamin Jr., MD, MPH,PhD3, Mukesh Patel, MD1,2, José Miró, MD, PhD4, Eugene Athan, MD5, Bruno Barsic, MD, PhD6, Emilio Bouza, MD,PhD7, Liliana Clara, MD8, Tom Elliott, PhD9, Zeina Kanafani, MD, MS10, John Klein, MD11, Stamatios Lerakis, MD12, Donald Levine, MD13, Denis Spelman, MD14, Ethan Rubinstein, MD, LL.B15, Pilar Tornos, MD16, Arthur J. Morris, MD17, Paul Pappas, MS18, Vance G. Fowler Jr, MD, MHS3, Vivian H. Chu, MD, MHS3, and Christopher Cabell, MD, MHS [on behalf of for the International Collaboration on Endocarditis-Prospective Cohort Study Group]3 1Department

NIH-PA Author Manuscript

of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, 1900 University Boulevard, 229 THT, Birmingham, Alabama, USA, 35294-0006 2Department of Medicine, Infectious Diseases Section, Birmingham Veterans Administration Medical Center, 700 19th Street South, Birmingham, Alabama, USA, 35233 3Department of Medicine, Duke University Medical Center, PO Box 1799, Durham, North Carolina, USA, 27715 4Department of Medicine, Infectious Disease Service, Institut d’Investigacions Biomediques August Pi i Sunyer-Hospital Clinic, University of Barcelona, Villarroel, 170, Barcelona, Spain, 08036 5Department of Infectious Diseases, Barwon Health, The Geelong Hospital, PO Box 281, Geelong, Victoria, Australia, 3220 6Department of Infectious Diseases, University Hospital for Infectious Diseases, Mirogojska 8, Zagreb, Croatia 7Department of Medical Microbiology, Hospital General Universitario Gregorio Marañón, Dr. Esquerdo 46, Madrid, Spain, 28007 8Hospital Italiano, Buenos Aires, Argentina 9Department of Clinical Microbiology and Infection Control, Queen Elizabeth Hospital, Edgbaston, Birmingham, United Kingdom, B15 2TH 10Department of Medicine, American University of Beirut

NIH-PA Author Manuscript

Corresponding Author: John W. Baddley, M.D., University of Alabama at Birmingham, Department of Medicine, Division of Infectious Diseases, 1900 University Boulevard, 229 Tinsley Harrison Tower, Birmingham, AL 35294-0006. Potential Conflicts of Interest JWB: Research support from Astellas and Merck, Inc. Speaker’s bureau for Merck and Enzon. Consulting services for Pfizer and Enzon. DKB: Research support from Astellas, Pfizer, Inc., Biosynexus, Cape Cod Associates, Inc, Johnson and Johnson, and Astra Zeneca. Fellowship support from Johnson & Johnson, and MedImmune. All monies go to Duke University. Dr. Benjamin does not own any stock or hold financial interest in any organization listed above. MP: None JM: None EA: None BB: Grant support from Croation Ministry of Science, No. 108-1080002-0102. Consulting services for Pliva Pharmaceuticals. Speaker’s bureau for Pliva Pharmaceuticals, Pharmasuiss Zagreb. Unrestricted research grant from Roche d.o.o Zagreb. EB: None LC: None TE: None ZK: None JK: None SL: None DL: None DS: None ER: Research support from Theravance, Daiichi, Replidyne. Consulting services for Pfizer, Bayer, Wyeth, Teva, Replidyne, Schering Plough, Atox, and BiondVax. PT: None AJM: None PP: None VGF: Research funding from Theravance, Merck, Nabi, Inhibitex, Cubist and the National Institutes of Health. Consulting for Astellas, Biosynexus, Cubist, Inhibitex, Merck, Johnson & Johnson; and is on the speakers’ bureaus for Cubist and Pfizer. VHC: None CC: None

Baddley et al.

Page 2

NIH-PA Author Manuscript

Medical Center, Beirut, Lebanon 11Department of Microbiology, St. Thomas' Hospital, 5th Floor North Wing, Lambeth Palace Road, London, United Kingdom, SE1 7EH 12Department of Medicine, Emory University, 1365A Clifton Road, NE, Atlanta, Georgia, USA, 30322 13Department of Medicine, Wayne State University, 4201 St. Antoine Boulevard, Detroit, Michigan, USA, 48201 14Department of Microbiology, The Alfred Hospital, Commercial Road, Melbourne, Victoria, Australia, 3004 15Department of Medicine, Section of Infectious Diseases, University of Manitoba, 543-730 William Avenue, Winnipeg, Manitoba, Canada, R3E0W3 16Department of Cardiology, Hospital Universitari Vall d'Hebron, P Vall d’Hebron 119-129, Barcelona, Spain, 08035 17Department of Microbiology, Auckland City Hospital, Grafton, Auckland, New Zealand 18Outcomes Research and Assessment Group, Duke Clinical Research Institute, Durham, North Carolina, USA, 17969 19ICE-PCS Study Group Investigators are Listed in the Appendix

Abstract Purpose—Candida infective endocarditis (IE) is uncommon but often fatal. Most epidemiologic data are derived from small case series or case reports. This study was conducted to explore epidemiology, treatment patterns, and outcomes of patients with Candida IE.

NIH-PA Author Manuscript

Methods—We compared 33 Candida IE cases to 2716 patients with non-fungal IE in the International Collaboration on Endocarditis - Prospective Cohort Study. Patients were enrolled and data collected from June 2000 until August 2005. Results—Patients with Candida IE were more likely to have prosthetic valves (p